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Abstract 20	
 The innervation of teeth mediated by axons originating from the trigeminal 21	
ganglia is essential for their function and protection. Immunosuppressive therapy using 22	
Cyclosporine A (CsA) was found to accelerate the innervation of transplanted tissues 23	
and particularly that of bioengineered teeth. To avoid the CsA side effects, we report in 24	
this study	 the preparation of CsA loaded poly(lactic-co-glycolic acid)	 (PLGA) 25	
nanoparticles, their embedding on polycaprolactone (PCL)-based scaffolds and their 26	
possible use as templates for the innervation of bioengineered teeth. This PCL scaffold, 27	
approved by the FDA and capable of mimicking the extracellular matrix, was obtained 28	
by electrospinning and decorated with CsA-loaded PLGA nanoparticles to allow a local 29	
sustained action of this immunosuppressive drug. Dental re-associations were co-30	
implanted with a trigeminal ganglion on functionalized scaffolds containing PLGA and 31	
PLGA/Cyclosporine in adult ICR mice during 2 weeks. Histological analyses showed 32	
that the designed scaffolds did not alter the teeth development after in vivo 33	
implantation. The study of the innervation of the dental re-associations by indirect 34	
immunofluorescence and transmission electron microscopy (TEM), showed that 88.4 % 35	
of the regenerated teeth were innervated when using the CsA-loaded PLGA scaffold. 36	
The development of active implants thus allows their potential use in the context of 37	
dental engineering. 38	
 39	
Statement of significance 40	
Tooth innervation is essential for their function and protection and this can be promoted 41	
in vivo using polymeric scaffolds functionalized with immunosuppressive drug-loaded 42	
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nanoparticles.  Immunosuppressive therapy using biodegradable nanoparticles loaded 43	
with Cyclosporine A was found to accelerate the innervation of bioengineered teeth 44	
after two weeks of implantation. 45	
 46	
Keywords 47	
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Nanoparticles 49	
 50	
1. Introduction  51	
 Dental caries, periodontal diseases and oropharyngeal cancers are the most 52	
prevalent oral diseases. Dental caries and tooth loss are important oral health indicators 53	
for adults and are key measures for monitoring progress of the disease [1]. The National 54	
Health and Nutrition Examination Survey, 2011–2012, revealed that in adults aged 20–55	
64, 91% had dental caries and 27% had untreated tooth decay. Only 48% of adults aged 56	
20–64 had a full set of permanent teeth (excluding third molars) and nearly 19% of 57	
adults aged 65 and over were edentulous [1]. Current dentures and implants used to 58	
replace missing teeth do not remodel and show a reduced integration with the host. 59	
Therefore, there is a need for new biomaterials to promote regeneration.        60	
 Regenerative nanomedicine is a rapidly expanding domain which has as 61	
objective the development of compatible biomaterials accepted by the body able to 62	
interact with cells/tissues present in the site of implantation. Such biomaterials can be 63	
combined with nanoparticles allowing a controlled or sustained release of active 64	
molecules. On the other hand, tissue engineering aims at replacing or repairing damaged 65	
tissues. 66	
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 Keller et al. [2] showed that cultured re-associations between dissociated 67	
mesenchymal cells and intact epithelium from Embryonic Day (ED) 14 mouse molars 68	
gave well formed teeth after implantation under the skin of adult ICR mice. The 69	
vascularization of the dental pulp occurred while the innervation was never observed 70	
[2]. Siemionow et al. [3] showed that, immunosuppressive therapy with tacrolimus, a 71	
calcineurin inhibitor, accelerated nerve regeneration in the case of face transplantation. 72	
Cyclosporine A (CsA), another calcineurin inhibitor, widely used in organ 73	
transplantation [4] has also direct effect on nerve growth [5,6]. When cultured re-74	
associations were co-implanted with trigeminal ganglia in CsA-treated ICR mice, the 75	
innervation of the dental mesenchyme occurred after one week of implantation. After 76	
two weeks, the axons coming from the trigeminal ganglia reached the odontoblasts. 77	
These results demonstrated that the innervation of the dental pulp can be obtained in 78	
immunosuppressive conditions [7]. However, the oral availability of CsA is slow and 79	
highly variable owing to its biopharmaceutical properties. The use of this molecule is 80	
controversial because it can induce different forms of kidney dysfunction, cancers and 81	
lymphomas [8,9]. Different approaches have been investigated to reduce its 82	
nephrotoxicity by developing CsA-loaded PLGA nanoparticles as delivery vehicles 83	
because of their excellent biocompatibility and sustained release [10].   84	
 On the other hand, the development of compatible biomaterials is also an 85	
essential step in the regeneration of a functional tooth as we previously showed by using 86	
a FDA approved nanofibrous polycaprolactone (PCL) scaffold functionalized with 87	
nerve growth factor (NGF) for a local release of this neurotrophic factor [11]. Indeed, 88	
when the scaffold was functionalized with nanoparticles containing NGF the 89	
innervation occurred in the dental pulp indicating the capability of the NGF 90	
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nanoreservoirs to direct axon formation from the trigeminal ganglion into the 91	
bioengineered tooth [11]. So, following this strategy it should be possible to fabricate a 92	
combination cell-therapy implant capable of regeneration of a vascularized and 93	
innervated tooth as tooth replacement during regenerative therapy. 94	
 The aim of this study was to combine a local sustained effect of CsA with the 95	
use of a PCL-based scaffold, using reduced doses of the immunosuppressant molecule 96	
and so avoiding the unwanted side effects attributed to the ingestion or burst release of 97	
this drug. For this purpose, we functionalized PCL scaffolds with CsA-loaded 98	
nanoparticles and studied the innervation in the bioengineered teeth pulp by 99	
immunofluorescence and transmission electron microscopy (TEM). 100	
 101	
2. Materials and Methods  102	
2.1. Materials  103	
 Poly (D, L-lactic acid/glycolic acid) 50/50 polymer (PLGA; MW 24-38 KDa), 104	
under the commercial name Resomer® RG 503 was purchased from Evonik Industries 105	
AG (Darmstadt, Germany). Polycaprolactone (PCL; MW 80 KDa) analytical grade, 106	
Cyclosporine A, Dexamethasone (used as HPLC internal standard), Pluronic® F-68 107	
surfactant, ethyl acetate (Class 3 solvent according to the pharmacopeia), acetonitrile 108	
and methanol (HPLC grade), were all purchased from Sigma Aldrich (St. Louis (MO), 109	
USA) and used as received. All references to water imply the use of MilliQ water 110	
previously filtered through a 0.2µm cellulose nitrate membrane.    111	
                                                                                                                                               112	
2.2. Synthesis of Cyclosporine A (CsA) loaded PLGA nanoparticles   113	
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 Cyclosporine loaded PLGA (PLGA/CsA) nanoparticles were prepared in a 114	
continuous microfluidic reactor using a PEEK-made interdigital micromixer (SIMM-115	
V2, Slit Interdigital Micro Mixer, IMM, Mainz, Germany) by carrying out an oil-in-116	
water (O/W) emulsification process followed by a solvent evaporation procedure. 117	
Briefly, 1% (w/v) of PLGA (50:50) polymer, 0.1% (w/v) of CsA and 2% (w/v) of 118	
Pluronic F68 (used as surfactant) were dissolved in 30 mL of ethyl acetate (used as 119	
organic solvent). This resulting organic phase was then mixed and emulsified with 120	
MilliQ water, interfaced using syringe pumps (Harvard Apparatus),	with flow rates of 121	
16 and 32 mL min-1, respectively. Both solutions were fed through a 1/16” PTFE tubing 122	
and then interfaced inside the PEEK-based interdigital micromixer. The micromixer 123	
was placed in an ice bath to control the reaction temperature. After the formation of a 124	
stable emulsion, the organic solvent was evaporated under continuous stirring (600 rpm) 125	
in an open flask during 3 h (Fig. 1). 126	
2.3. Characterization techniques  127	
 Scanning electron microscopy (SEM, Inspect F50, FEI, Eindhoven, The 128	
Netherlands) was employed to determine the shape of the synthesized PLGA NPs. The 129	
freshly prepared nanoparticles were mixed during 1.5 h with the same volume of 130	
phosphotungstic acid solution (7.5% w/v) used as contrast agent. The dispersion was 131	
then centrifuged and washed three times with Milli Q water and later re-suspended. A 132	
drop of the resulting nanoparticle suspension was placed on a glass slide, air dried and 133	
coated with platinum under vacuum before SEM observation.  Nanoparticle size, size 134	
distribution and zeta potential (pH 7.2) were determined by dynamic light scattering 135	
(Zeta Plus, Brookhaven Instruments Corporation, NY) after appropriate dilution with 136	
Milli Q water. At least five replicate measurements were recorded in each case. CsA 137	
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content in PLGA nanoparticles was determined directly by dissolving the drug loaded 138	
nanoparticles in a solvent composed of acetonitrile and dexamethasone as HPLC 139	
internal standard. Then, methanol was added and the mixture was placed in a sonifier 140	
bath for 15 min to promote PLGA precipitation. The resulting dispersion was 141	
centrifuged at 12000 rpm for 20 min to remove the polymeric residue and the 142	
supernatant was filter using 0.22 µm PTFE syringe filters and placed in a vial for HPLC 143	
analysis. Experiments were performed in triplicate. CsA content in the samples was 144	
then determined by HPLC (Waters Instrument 2690 Alliance, USA). A Kinetex C18 145	
column with a 2.6 µm particle size filler and column dimensions of 50 mm × 4.6 mm 146	
was used. The mobile phase consisted in a 80:20 (v/v) mixture of acetonitrile:water 147	
including a phosphoric acid concentration of 200 ppm. The detector wavelength, 148	
injection volume, flow rate, and column temperature were 210 nm, 5 µL, 0.5 mL min-1 149	
and 70 °C, respectively. The HPLC method was validated with respect to linearity, 150	
repeatability and the limit of quantification and limit of detection. Drug encapsulation 151	
efficiency (EE) and drug loading (DL) were calculated using the following equations: 152	
	 Equation (1)																EE % =   !"#$%& !" !"#$ !"#$%$ 
!"#$% !"#$%& !" !"#$ !"#$
 x 100	153	
	 Equation (2)              D L % =   !"#$%& !" !"#$ !"#$%$ 
!"#$%& !" !"#$
 x 100	154	
In vitro drug release studies were carried out using a mini dialysis cassette composed of 155	
a 20000 molecular weight cut-off cellulose dialysis membrane (Slide-A-Lyzer, Fischer).  156	
The CsA-PLGA nanoparticles in suspension (2 ml with a concentration of 9 mg/ml) 157	
were loaded into the dialysis cassette which was immersed in a conical tube with 44 mL 158	
of PBS containing 1% (w/v) of tween 80. The tubes were placed in an incubator 159	
thermostatted at 37ºC under oscillation at 100 rpm. At predetermined intervals, samples 160	
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of the CsA-PLGA were collected and washed by centrifugation. Finally, the entrapment 161	
efficiency protocol described above was used to open the nanoparticles and directly 162	
determine the drug concentration remaining in the sample at each time point using 163	
HPLC.   164	
2.4. PCL scaffold synthesis and functionalization 165	
 PCL was dissolved in a mixture of dichloromethane/dimethylformamide 166	
(DCM/DMF 50/50 v/v) at 15% wt/v and stirred overnight before use. A standard 167	
electrospinning set-up (EC-DIG apparatus, IME Technologies, Eindhoven, Netherlands) 168	
was used to fabricate the PCL scaffolds. The PCL solution was poured into a 5 mL 169	
syringe and ejected through a needle with a diameter of 0.5 mm at a flow rate of 1.2 mL 170	
h-1, with a programmable pump (Harvard apparatus). A high-voltage power supply 171	
(SPELLMAN, SL30P10) was used to set 15 kV at the needle. Aluminum foils (20x20 172	
cm2), connected to the ground collector at a distance of 17 cm from the needle, were 173	
used to collect the electrospun PCL scaffold. PCL scaffolds dried in vacuum oven 174	
overnight to remove traces of solvent and then functionalized by the layer-by-layer 175	
method. All rinse solution used was Tris buffer 20mM/NaCl 0.15 M at pH 7.4. PCL 176	
scaffolds were incubated in a poly-L-lysine solution (PLL, 500mg/mL) for 15 min, 177	
rinsed with the buffer for 15 min, and then incubated in PLGA or PLGA/CsA 178	
nanoparticles solution for 15 min and finally thoroughly washed for 15 min, thus 179	
constructing a “bilayer” (PLL/PLGA/CsA) on the fiber surface. Repeating this protocol 180	
five times allowed the construction of (PLL/PLGA/CsA)5, respectively. Even though 181	
this buffer solution provides with high ionic strength to the media, the nanoparticles 182	
remained strongly bound to the PLL electrospun nanofibers as it can be seen in figures 183	
2f and g. 184	
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2.5. Molar ED14 culture, implant preparation and in vivo implantation 185	
 The first lower molars were dissected from ICR mouse (Charles River 186	
Laboratories, l’Arbresle, France) embryos at Embryonic Day 14 (ED14). The 187	
experimental protocol fulfilled the authorization of the “Ministère de l’Enseignement 188	
Supérieur et de la Recherche” under the agreement number 01715.01. The Ethics 189	
Committee of Strasbourg named "Comité Régional d'Ethique en Matière 190	
d'Expérimentation Animale de Strasbourg (CREMEAS)" specifically approved this 191	
study. For the innervation experiments, molars were cultured for 6 days on semi-solid 192	
medium as previously described [7]. They were then associated with the trigeminal 193	
ganglion (TG) on PCL scaffolds (functionalized by PLL/PLGA or PLL/PLGA/CsA) for 194	
one night, before subcutaneous implantation for 2 weeks in adult ICR mice. 195	
2.6. Histology and indirect immunofluorescence 196	
 For histology, after 2 weeks implantation, some implants were fixed for 24 h in 197	
Bouin-Hollande and embedded in paraffin. Serial sections (7 µm) were stained with 198	
Mallory’s stain. Sections were observed in a Leica DM4000B microscope. Other 199	
implants were embedded in Tissue-Tek, frozen at -20°C and sectioned (10µm) using a 200	
cryostat (Leica, CM3000). Serial sections were rinsed with PBS and fixed for 10 min 201	
with 4% paraformaldehyde at 4°C. After washing three times for 5 min in PBS at room 202	
temperature, sections were incubated for 30 min at room temperature in a blocking 203	
solution of 1% bovine serum albumin (BSA) and 0.1% Triton X100 and then incubated 204	
for one night at 4°C with the primary antibodies (Table 1). After washing with PBS, 205	
sections were incubated with secondary antibodies (Molecular Probes, Invitrogen) 206	
(Table 1). Nuclei were stained with 4’, 6-diamidino-2-phenylindole (DAPI, Euromedex, 207	





primary antibody or using normal goat serum (NGS). After 3 additional washes in PBS, 209	
slides were mounted in fluorescence mounting medium (Dako, Trappes, France) and 210	
observed with a fluorescence microscope (Leica DM4000B).  211	
Table 1. Primary and secondary antibodies used for indirect immunofluorescence  212	
 213	
 214	
2.7. Scanning and transmission electron microscopies 215	
 For the morphological study by scanning electron microscopy (SEM), PCL 216	
scaffolds were fixed (4% paraformaldehyde) and dehydrated (successive baths in 25, 217	
50, 75, 90, 100% ethanol) and treated with Hexamethyldisilazane (HDMS). They were 218	
stuck on a supporting sample holder using carbon conductive adhesive, then silver-219	
coated and observed with a Philips XL-30 ESEM scanning electron microscope in 220	
conventional mode (high vacuum) with a Thornley-Everhart secondary electron 221	
detector. For transmission electron microscopy (TEM) observations, samples were fixed 222	
by immersion in 2.5% glutaraldehyde and 2.5% paraformaldehyde in cacodylate buffer 223	

















































at 4°C and dehydrated through graded alcohol series (50, 70, 90, 100%) and propylene 225	
oxide for 30 min each under agitation. Samples were embedded in Epon 812. Semi-thin 226	
sections were cut at 2 µm with an ultra-microtome (Leica Ultracut UCT), stained with 227	
toluidine blue and histologically analyzed by light microscopy. Ultra-thin sections were 228	
cut at 70 nm and contrasted with uranyl acetate and lead citrate and examined at 70 kV 229	
with a Morgagni 268 D electron microscope. Images were captured digitally by using a 230	
Mega View III camera (Soft Imaging System). 231	
 232	
2.8. Statistical analysis 233	
 The association of cyclosporine with dental development and its association with 234	
innervation were evaluated by using the Pearson χ2 test. The commercial software 235	
GraphPad Prism 7.0 for Windows (GraphPad Software Inc.) was used for carrying out 236	
the statistical analyses and graphics. Differences between groups were considered 237	
significant at P<0.05. 238	
 239	
3. Results  240	
3.1. Characterization of the nanoparticles and scaffolds 241	
 The experimental set up for the continuous synthesis of the CsA-loaded PLGA 242	
nanoparticles is depicted in Fig. 1. The synthesis is based on the use of microfluidic 243	
platforms (PEEK-based interdigital static micromixer) to achieve a narrow nanoparticle 244	
monodispersity with a high throughput and avoiding batch-to-batch product variations. 245	





a skilled technician is not required. Those nanoparticles were prepared by an Oil/Water 247	
(O/W) microchannel emulsification process and solvent evaporation method. 248	
 It is important to point out that by using microfluidics no external shear forces 249	
are needed compared to the traditional batch production where ultrasonic or mechanical 250	
(i.e., homogenizer) forces are needed to form a stable emulsion. Consequently we were 251	
able to synthesize CsA-loaded PLGA nanoparticles with just the microfluidic platform. 252	
Figure 2 (a-d) shows the morphology of the CsA-loaded PLGA nanoparticles produced 253	
in a continuous fashion. Particle sizes of 214 ± 71 nm and 254 ± 63 nm were obtained 254	
from the SEM micrograph analysis (N=50) and from DLS (hydrodynamic diameter), 255	
respectively. The zeta potentials obtained at physiological pH were -36.33 ±0,21 mV 256	
and -28.53 ± 0,41 mV for the PLGA and for the CsA-loaded PLGA nanoparticles, 257	
respectively. HPLC analysis revealed an encapsulation efficiency and drug loading of 258	
89.6 ± 4.5 % and 9.0 ± 0.4 %, respectively (see definitions in Materials and Methods 259	
section).  260	
 The in vitro drug release analysis revealed that after a short induction period a 261	
zero order sustained release was achieved and in 14 days a 71% of the encapsulated 262	
drug was released from the nanoparticles (see Figure 1 in the Supporting Information 263	
section).  264	
The PCL scaffolds (Fig. 2e) evidenced a non-woven mesh like structure with a 265	
large surface area per volume ratio. Figure 2 (f,g) shows how the CsA-loaded PLGA 266	
nanoparticles remained tightly grafted on the surface of the electrospun nanofibers. The 267	
layer-by-layer technique was used to decorate the surface of the nanofibers with the 268	
PLGA nanoparticles containing the immunosuppressant drug. The preliminary gamma 269	





hydrophilisation of PCL, accompanied by a certain percentage of PCL carbonyl bonds 271	
hydrolytic cleavage, leading to the appearance of hydroxyls. This altogether enables the 272	
physical adsorption of a first “layer” of cationic polyelectrolyte poly-L-lysine (PLL), 273	
allowing further electrostatic attachment of the negatively charged CsA-loaded PLGA 274	
nanoparticles. 275	
 276	
3.2. Histology of bioengineered teeth implanted for two weeks on (PLL/PLGA/CsA)5 277	
scaffolds  278	
 The development of the re-associations seeded on (PLL/PLGA/CsA)5 scaffolds 279	
and implanted under the skin of ICR mice for two weeks was evaluated by histological 280	
analysis using Mallory’s staining (Fig. 3). Well formed teeth developed: the crown was 281	
constituted by several cusps (Fig. 3a) and the formation of root was initiated (Fig. 282	
3a,c,d,h). Blood vessels were observed in all the dental pulp and reached the 283	
odontoblastic layer (Fig. 3c,g). Odontoblasts were elongated and polarized, their 284	
nucleus was on the opposite site of the secretory pole (Fig. 3c,g). Functional 285	
odontoblasts secreted polarized predentin/dentin (Fig. 3b,c,e,g). Dentinal tubules 286	
present in the predentin/dentin reached the dentin-enamel junction (Fig. 3e). Elongated 287	
ameloblasts were polarized and functional with the synthesis and secretion of the 288	
enamel organic matrix (Fig. 3b,e,f). Ameloblasts were in contact with the cells of the 289	
stratum intermedium also responsible for the tooth enamel formation (Fig. 3f). 290	
Cementoblasts were detected on the surface of the root dentin and secreted the 291	
cementum (Fig. 3h).  292	
 293	
 294	





(PLL/PLGA/CsA)5 scaffolds in ICR mice 296	
 Cultured re-associations were co-implanted with trigeminal ganglia for two 297	
weeks on PCL scaffolds functionalized with (PLL/PLGA)5 or (PLL/PLGA/CsA)5 under 298	
the skin of ICR adult mice. In both these conditions teeth developed with a well formed 299	
crown and initiation of the root development as shown by immunostaining experiments 300	
(Fig. 4a-d). Antibodies against peripherin were chosen to visualize nerve fibers and 301	
against CD31 to detect blood vessels (Fig. 4a-e). In both these conditions re-302	
associations were fully vascularized (Fig. 4a-d). Nerve fibers did not enter the dental 303	
pulp after implantation with PCL (PLL/PLGA)5 scaffolds (Fig. 4a,b). Nerve fibers 304	
coming from the trigeminal ganglion were detected only in the tissues surrounding the 305	
bioengineered teeth at the limit between the dental pulp and the peridental mesenchyme 306	
(Fig. 4b). On the other hand, after 2 weeks implantation on CsA-containing PCL 307	
scaffolds (PLL/PLGA/CsA)5, nerve fibers were detected in the central part of the dental 308	
pulp (Fig. 4c-e) and near the odontoblastic layer (Fig. 4d, white square). Nerve fibers 309	
were also positive for NF200 (Fig. 4f,h). Complexes between nerve fibers and immature 310	
blood vessels positive for CD31 were formed all over the dental pulp (Fig. 4e,f). 311	
 Odontoblasts were characterized by immunostaining for nestin (Fig. 4g,h), a 312	
marker for differentiated odontoblasts [12,13]. GAP43 is an intracellular growth 313	
associated-protein which participates in neuronal and branching during development 314	
and regeneration. Staining for GAP43 allowed the visualization of growth cone at the 315	
tip of axons (Fig. 4g). Double stainings for GAP43 and nestin showed the presence of 316	
GAP43 in the odontoblastic layer (Fig. 4g). The nerve fibers had reached the basal pole 317	
of the odondoblasts and were also present between the odontoblasts (Fig. 4g,h). Glial 318	





and glial fibrillary acidic protein (GFAP) for the detection of satellite glial cells (Fig. 320	
4i). We observed that there are more positive cells for S100β than for GFAP. 321	
 Transmission electron microscopy (TEM) showed that in the dental pulp of the 322	
bioengineered teeth only unmyelinated axons with low diameter (between 0.5 µm and 1 323	
µm) were present (Fig. 5), while in the trigeminal ganglion there were myelinated and 324	
unmyelinated axons. Axons were detected in the dental pulp (Fig. 5a), in the vicinity of 325	
blood vessels (Fig. 5b) and near the odontoblasts (Fig. 5c). In axons, microtubules and 326	
numerous mitochondriae were observed (Fig. 5). At higher magnification (Fig. 5b’), the 327	
diameter of the microtubules could be estimated as 25 nm. 328	
 For comparison, seven independent experiments were performed by co-329	
implanting re-associations with trigeminal ganglia on (PLL/PLGA)5 functionalized 330	
scaffolds (total number of implants N=19) or on (PLL/PLGA/CsA)5 functionalized 331	
scaffolds (total number of implants N=65) during 2 weeks in ICR mice (see the 332	
Supporting Information section, Table 1). 66.15% of the (PLL/PLGA/CsA)5 implants 333	
regenerated teeth with blood vessels. 88.4% of these formed teeth contained peripheral 334	
axons coming from the trigeminal ganglion which colonized the dental pulp up to the 335	
odontoblastic layer. 63.15% of (PLL/PLGA)5 implants contained vascularized teeth but 336	
nerve fibers stayed in the peridental mesenchyme without going into the dental pulp 337	
(see the Supporting Information section, Table 1). Statistical analyses (Figure 6) showed 338	
that there was no link between the presence or absence of cyclosporine on the teeth 339	
development (p=0.9117). On the other hand, the same statistical aanalysis showed that 340	







 The PLGA nanoparticles, widely used in tissue engineering applications, were 344	
prepared in a continuous manner by an O/W emulsification process and solvent 345	
evaporation method in a microfluidic reactor. It is important to point out that the 346	
emulsion was formed without the aid of external mechanical forces (i.e., ultrasonic 347	
sources or homogenizers), but only using the shear stress caused by the fluid flow 348	
through microfluidic interdigital channels [14]. The polyester PLGA, approved by the 349	
FDA in many applications, is biocompatible and biodegradable by hydrolysis of its ester 350	
linkages under physiological conditions and excreted from the body as carbon dioxide 351	
and water via the Krebs cycle [15,16]. Drug release kinetics of PLGA-encapsulated 352	
drugs depend initially on a diffusion-controlled mechanism and at the end of its 353	
degradation on an erosion-controlled mechanism. Degradation rates can be tuned 354	
depending on the ratio between both monomers, the 50:50 ratio being the one which 355	
exhibits the fastest degradation [14]. In this work, the use of this emulsification 356	
technique based on microfluidics was effective because the encapsulation efficiency 357	
reached was very high 89.6 ± 4.5 % and a drug loading of 9.0 ± 0.4 % was obtained. 358	
 The use of these nanoparticles is essential for the functionalization of the PCL 359	
scaffolds because the loading levels using the free drug are very low compared to the 360	
encapsulation of the drug inside PLGA nanoparticles. Other nanoparticles such as 361	
liposomes have been used for the CsA encapsulation to achieve sustained release 362	
systems [9,10]. The technique of hot homogenization followed of ultrasonication was 363	
used for encapsulation of the cyclosporine [10]. The encapsulation of this drug has been 364	
applied in the treatment of infectious digestive diseases, and it was observed that 365	
encapsulated CsA showed improved mucosa absorption and reduced side effects [9,10]. 366	





suspension of CsA-loaded nanoparticles has been applied in the treatment of psoriasis, 368	
showing an improved outcome [17]. Therefore, the encapsulation of CsA in 369	
biodegradable matrices allows a sustained release and reduced unwanted side effects. 370	
 PCL scaffolds have already been applied in bone regeneration [18]. The layer-371	
by-layer technique allows controlling the deposition in a sequential manner of drug-372	
eluting nanoparticles on the surface of the PCL fibers. The use of this technique is 373	
perfectly adapted to tissue engineering because the molecules incorporated on the 374	
scaffold remain active both without degradation and without showing a premature 375	
release [19]. In addition, an on-demand release triggered by the presence of cells is 376	
achievable by using drug-loaded nanoreservoirs decorating the surface of the scaffold 377	
nanofibers. The advantage of this technique is that the amount of active molecules can 378	
be controlled through the number of layers on the PCL scaffolds, and consequently the 379	
duration of the release. In summary, the use of drug-eluting nanoparticles decorating the 380	
surface of scaffolds allows a local action of the active principle with lower doses than 381	
the conventional systemic treatment and consequently decreases the risk of toxicity 382	
associated to the uncontrolled release of the free molecule. 383	
 The development of teeth which formed after two weeks implantation on 384	
(PLL/PLGA/CsA)5 scaffolds in ICR mice did not show any differences with those 385	
forming after 2 weeks implantation without scaffold [20]. Indeed, the cellular re-386	
associations reached a stage of development equivalent to that of a 4 days postnatal first 387	
lower molar (PN4) with a similar crown development and identical mineralization 388	
[2,11,20]. To detect axons in the bioengineered teeth, we chose anti-Nf200 and anti-389	
peripherin antibodies. NF200 is expressed in axons from central and peripheral nervous 390	





Both antibodies detect the axons coming from the trigeminal ganglia innervating teeth 392	
in vivo [21]. 393	
 88.4% of the teeth regenerated on (PLL/PLGA/CsA)5 scaffolds contained 394	
peripheral axons coming from the trigeminal ganglion which colonized the dental pulp 395	
up to the odontoblastic layer. Identical results were obtained in the case of the co-396	
implantation of re-associations cultivated during 7 days with a trigeminal ganglion, 397	
implanted during 2 weeks in a ICR mouse treated with CsA [7].  Indeed, in this case, 398	
91.5% of teeth obtained after 2 weeks of implantation in ICR mice treated with CsA in 399	
the drinking water were innervated [7]. We can thus conclude that our method of 400	
associating a functionalized PCL scaffold with CsA-loaded PLGA nanoparticles is 401	
sufficient to obtain innervated teeth and can avoid the side effects related to the 402	
ingestion of CsA. 403	
 The growth cones positive for GAP43 were present only in the odontoblastic 404	
layer in the physiological teeth after birth, forming the mechanic sensory complex [22].  405	
According to Kökten et al. [23] the double staining of the growth cones and 406	
odontoblasts did not show the presence of growth cones in the odontoblastic layer in re-407	
associations implanted during 2 weeks in "nude" mice. On the other hand, re-408	
associations co-implanted with a trigeminal ganglion during 2 weeks with CsA-loaded 409	
PLGA based scaffolds contained growth cones at the level of the odontoblastic layer. 410	
Besides its immunosuppressive action, CsA stimulates the growth of nerve fibers by 411	
inducing the expression of the protein GAP43 in the growth cones which could explain 412	
the obtained results [24]. In the supporting information section we have included a 413	
diagram (see the Supporting Information section, Figure 2) and discussion about the 414	





 The staining of glial cells with anti-S100ß and anti-GFAP antibodies showed 416	
that several populations of glial cells were present in the dental pulp of re-associations 417	
implanted with the trigeminal ganglion on functionalized (PLL/PLGA/CsA)5 scaffolds 418	
during 2 weeks. The same results were observed for re-associations implanted in "nude" 419	
mice, where glial cells were identified in the dental pulp [23]. Several conditions were 420	
tested and we observed that these cells were present in the dental pulp in the absence of 421	
trigeminal ganglion (data not shown). Thus, these cells did not come from the 422	
trigeminal ganglion, as it had been previously suggested [23]. The co-localization 423	
between positive GFAP cells and axons coming from the trigeminal ganglion in 424	
immunosuppressive conditions suggests cellular communication between these cells. 425	
Studies revealed that the positive GFAP and S100ß positive cells secrete numerous 426	
cytokines and growth factors such as neurotrophins which favor the axonal survival and 427	
regeneration [25,26]. Their origin and their action within the dental pulp remain to be 428	
determined. 429	
 TEM results showed that the fibers which innervate the teeth dental pulp 430	
obtained after 2 weeks of implantation with (PLL/PLGA/CsA)5 scaffolds, were 431	
unmyelinated. They also confirmed the relationship between axons and blood vessels 432	
because unmyelinated fibers were in contact with endothelial cells surrounding blood 433	
vessels. In the physiological conditions, myelinated and unmyelinated axons were 434	
observed in the dental pulp of adult rat [27]. It was shown that a nervous lesion leads to 435	
a decrease in the number and the diameter of myelinated axons. This decrease in the 436	
axon diameter could generate a demyelination [27].  Under our experimental conditions, 437	
the dissection of the trigeminal ganglion probably generated this process. Thus, we 438	
could suppose that these axons which innervated the dental pulp of the implants were of 439	






 In conclusion, we developed an implant consisting of an electrospun nanofibrous 442	
scaffold functionalized with CsA-loaded PLGA nanoparticles produced by a continuous 443	
emulsification process. By using microfluidic reactors it is possible to produce CsA-444	
loaded PLGA nanoparticles with a narrow particle-size distribution and elevated 445	
encapsulation efficiency. The layer-by-layer technique allows the deposition of PLGA 446	
nanoparticles on electrospun PCL nanofibers in a controlled manner. The proposed 447	
system has successfully allowed the innervation of tooth buds. This strategy was 448	
validated in vitro and in vivo and shows its potential application in clinical settings.   449	
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Captions 544	
Fig. 1. Experimental set up for the synthesis of PLGA/CsA nanoparticles. PEEK-based 545	
interdigital static micromixer (a). Geometry of the inlet stream to assure an equalized 546	
flow distribution into the mixing microchannels (b). Detail of the microchannel 547	
dimensions (c). Experimental process with the flow rates and stream compositions used 548	
and the sequential synthesis, solvent evaporation and polymer precipitation (d). 549	
Fig. 2. SEM (a,b) and TEM (c,d) observation of the resulting CsA-loaded PLGA 550	
nanoparticles and SEM visualization of the PCL scaffolds consisting of non-woven 551	
electrospun nanofibers (e) grafted with CsA-loaded PLGA nanoparticles after 3	layer-552	
by-layer coatings (PLL/PLGA/CsA)3 (f) or 5 (PLL/PLGA/CsA)5 (g). Bars = 3 µm in a 553	
and b, 200 nm in c, 50 nm in d, 1.5 µm in e and 2.5 µm in f and g. 554	
Fig. 3. Histology of bioengineered teeth implanted on the PCL scaffolds functionalized 555	
with CsA-loaded PLGA nanoparticles ((PLL/PLGA/CsA)5) for 2 weeks in ICR mice. e 556	
and f are magnifications of the selected areas in b which show mineralized matrices and 557	
polarized and differentiated ameloblasts respectively. g is a magnification of the 558	





with blood vessels. h is a magnification of the selected area in d which shows the 560	
cementoblasts in contact with the root dentin. Am, ameloblast; BV, blood vessel; Cb, 561	
cementoblast; D, dentin; DEJ, dentin-enamel junction; DP, dental pulp; DT, dentinal 562	
tubule; E, enamel; Od, odontoblast; pD, predentin; PDL, periodontal ligament; PDM, 563	
peridental mesenchyme; SI, stratum intermedium; TG, trigeminal ganglion. Bars = 100 564	
µm in a, 25 µm in b-d and 10 µm in e-h. 565	
 566	
Fig. 4. Innervation of bioengineered teeth after implantation based on the PCL scaffolds 567	
functionalized with (PLL/PLGA)5 (a,b) and (PLL/PLGA/CsA)5 (c-i).  Bioengineered 568	
teeth were analyzed immunohistochemically by using selected antibodies as biomarkers 569	
for nerve fibers (peripherin, red) and blood vessels (CD31, green) (a-e), which showed 570	
that nerve fibers and blood vessels entered the dental pulp after 2 weeks when using 571	
PCL (PLL/PLGA/CsA)5 scaffolds (c-e) and that nerve fibers were associated with blood 572	
vessels (d and e, white arrowheads). d is a magnification of the dental pulp. On the other 573	
hand by using (PLL/PLGA)5  scaffolds only, nerve fibers stayed in the peridental 574	
mesenchyme (a,b). Nerve fibers were also stained by NF200 (f,h). They were associated 575	
with blood vessels (f, white arrowheads). After 2 weeks of implantation, odontoblasts 576	
were stained by an anti-nestin antibody (g,h) and growth cones by an anti-GAP43 577	
antibody (g, white arrows). In this case, nerve fibers reached the odontoblast layer (g,h). 578	
Immunofluorescence detection of S100β protein and GFAP (i) showed the presence of 579	
glial cells as Schwann cells (S100β) and satellite glial cells (GFAP) in the dental pulp.	580	
BV, blood vessel; DP, dental pulp; Od, odontoblast; PDM, peridental mesenchyme; TG, 581	
trigeminal ganglion. Bars = 200 µm in a and c, 100 µm b and d, 25 µm in e,f and g and 582	





Fig. 5. Innervation of bioengineered teeth implanted on the PCL scaffolds 584	
functionalized with CsA-loaded PLGA nanoparticles observed by TEM. Unmyelinated 585	
axons originating from the trigeminal ganglion and containing numerous mitochondria 586	
and microtubules were present in the dental pulp (a) and near the odontoblastic layer 587	
(c). An axon was detected near a blood vessel in the dental pulp (b). Note that the 588	
diameter of the microtubules was approximately 25 nm (b’). Ax, unmyelinated axon; 589	
BV, blood vessel; DP, dental pulp; EC, endothelial cell; m, mitochondria; mt, 590	
microtubule; Od, odontoblast; RER, rough endoplasmic reticulum. Bars = 0.5 µm in a,b 591	
and c and 0.1 µm in b’.	592	
Fig. 6. Effect of CsA-loaded nanofibers on tooth formation and innervation of 593	
bioengineered teeth. Values with asterisks are significantly different ** P<0.01. 594	
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